Your session is about to expire
← Back to Search
UCD19 CAR T Cells for B-Cell Lymphoma
Study Summary
This trial will test whether it is possible to modify a person's own immune cells to kill B-cell NHL that has relapsed or is refractory to chemotherapy, and whether it is possible to do this without severe side effects.
- Non-Hodgkin's Lymphoma
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have received a type of medication called monoclonal antibody therapy within the past 14 days.There are no other treatments that can cure your condition, as decided by your main doctor.You do not currently have Graft-versus-Host Disease (GvHD).The doctor thinks that cellular therapy is not a good option for you, for any reason.You have received any type of gene therapy or CAR T cell therapy in the past.You have a current, ongoing condition affecting your brain or spinal cord.You have received a stem cell transplant from another person within the past 90 days and have been on immunosuppressive therapy for at least 4 weeks.You have tried and didn't benefit from at least two different types of treatment.You are not eligible if you cannot receive a type of treatment called CD19 CAR T Cells, which is available to the public.
- Group 1: UCD19 CAR T Cells
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
To what population is this research opportunity available?
"This medical research is searching for 11 volunteers who suffer from lymphoma and fall within the 18 to 80 year old age bracket. In addition, potential participants must fulfill certain requirements such as: Willingly agree to all procedures of the study, Have experienced failures with two or more systemic treatments, Be male or non-pregnant/non-lactating female adults between 18-80 years old., Achieve a performance status according to the Eastern Cooperative Oncology Group no higher than 2, Not be eligible to receive commercially available CD19 CAR T Cells., And have an intermediate form of lymphoma that falls somewhere between Burkitt and DLBC"
How hazardous is the deployment of UCD19 CAR T Cells for humans?
"The relative safety of UCD19 CAR T Cells is rated as a 1 on the scale due to this being an early-stage trial with only small amounts of data available regarding efficacy and general safety."
Is this research recruiting participants right now?
"The clinical trial listed on clinicaltrials.gov is no longer accepting patients, despite its initial posting date of July 17th 2020 and most recent update from September 1st 2022. Nevertheless, there are currently 1,796 other studies that require participants."
Are those over 35 years of age eligible for participation in this trial?
"This clinical trial has designated the age range of 18-80 as its eligibility criteria for participants."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger